Welcome to our dedicated page for Akari Therapeutics Plc news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc stock.
Akari Therapeutics Plc (AKTX) is a clinical-stage biopharmaceutical company advancing innovative treatments for rare autoimmune and inflammatory diseases. This page provides investors and industry observers with timely updates on the company’s clinical developments, regulatory milestones, and strategic initiatives.
Access comprehensive coverage of AKTX’s progress, including press releases on trial results, FDA designations, and partnership announcements. Our curated news collection focuses on developments related to coversin, nomacopan, and other pipeline candidates targeting complement-mediated disorders.
Key updates include progress in treating conditions like HSCT-TMA and Geographic Atrophy, manufacturing partnerships, and scientific presentations. All content is verified from primary sources to ensure accuracy for investment research and market analysis.
Bookmark this page for centralized access to AKTX’s latest developments in complement system therapeutics. Check regularly for objective updates on clinical advancements and corporate announcements relevant to biopharmaceutical investors.
Akari Therapeutics announces a cooperative research and development agreement with the U.S. Army Institute of Surgical Research (USAISR) to study nomacopan for trauma treatment. This investigational drug targets inflammation in trauma cases, showing promise in conditions like traumatic brain injury and myocardial infarction. The study aims to evaluate nomacopan's efficacy in preclinical trauma models. With trauma being a leading cause of death under 45 years, Akari aims to address the lack of approved therapies, potentially benefiting both military and civilian patients.
Akari Therapeutics (Nasdaq: AKTX) announced new findings published in CELLS revealing the role of LTB4 in promoting VEGF-related retinal inflammation, contributing to wet AMD. In preclinical models, PAS-nomacopan, a long-acting version of their drug, significantly reduced neo-vascularization equivalent to the FDA-approved Eyelea®. The study demonstrated over 50% reduction in VEGF levels in uveitis models, highlighting PAS-nomacopan's dual mechanism of action that inhibits both LTB4 and complement C5, potentially offering new treatment avenues for eye diseases.
Akari Therapeutics (Nasdaq: AKTX) is advancing its therapeutic candidate, votucalis, which inhibits histamine and targets chronic neuropathic pain and dermatological conditions. New pre-clinical data demonstrate votucalis's effectiveness in blocking neuropathic pain symptoms and treating atopic dermatitis. Unlike conventional opioids, votucalis acts peripherally, minimizing CNS-related side effects. Local administration showed superior results compared to systemic treatment. Akari aims to initiate Phase II trials in 2022, positioning votucalis as a potential innovative solution in pain management and inflammatory diseases.
Akari Therapeutics, Plc (Nasdaq: AKTX) announced CEO Clive Richardson will participate in two upcoming virtual investor conferences. The H.C. Wainwright BioConnect Conference will feature an on-demand presentation starting January 11, 2021. The ICR Conference 2021 is scheduled for January 14, 2021, at 10:00 a.m. ET. Investors can arrange virtual meetings during the ICR Conference. Akari develops therapies targeting orphan autoimmune and inflammatory diseases, with its lead drug candidate, nomacopan, inhibiting complement C5 and leukotriene B4 systems.
Akari Therapeutics, Plc (AKTX) announced progress in its clinical programs, including a pivotal Phase III trial for bullous pemphigoid (BP) expected to start in H1 2021, and enrollment for pediatric HSCT-TMA beginning in Europe. The company reported third-quarter financial results showing a net income of $1.4 million, reversing a loss from the previous year, largely due to increased other income and R&D tax credits. However, ongoing COVID-19 challenges may delay clinical trials and operations, impacting timelines. Cash as of September 30, 2020, stood at approximately $12.3 million.
Akari Therapeutics announced promising results from a long-term study of nomacopan for patients with paroxysmal nocturnal hemoglobinuria (PNH). New data from 19 patients indicates that nomacopan is well-tolerated and has achieved a 79% transfusion independence rate among formerly transfusion-dependent patients treated for at least six months. The study demonstrated a significant reduction in monthly blood transfusions, with a 77% decline in unit requirements. These findings support nomacopan's potential for treating other complement dysregulation disorders, as noted by the company’s CEO.
Akari Therapeutics (Nasdaq: AKTX) announced findings from a two-year research collaboration with University College of London, highlighting the potential role of leukotriene B4 (LTB4) in retinal inflammation and degeneration. The study showed that the therapeutic administration of nomacopan effectively reduced retinal damage and inflammation in autoimmune uveitis models, rivaling the efficacy of standard steroid treatment, dexamethasone. Key findings reveal the decrease in Th17 cell and macrophage activity, indicating nomacopan's promise as a safer alternative to corticosteroids, which have significant side effects.
Akari Therapeutics has announced positive Phase II trial results for nomacopan, an experimental treatment for bullous pemphigoid (BP), a severe autoimmune disease. The FDA and EMA have approved progression to a Phase III randomized placebo-controlled study, which is set to begin in H1 2021. Nomacopan has received orphan drug designation in the U.S. and Europe. The upcoming poster presentation at the EADV Congress on October 29, 2020, will detail the safety and efficacy data. BP affects over 100,000 patients in the U.S. and Europe, with current treatments often resulting in severe side effects.
Akari Therapeutics (Nasdaq: AKTX) has received FDA clearance to proceed with a multi-center, double-blind randomized clinical study of its drug nomacopan for treating COVID-19 pneumonia in the U.S. and Brazil. This follows positive results from initial studies indicating effective use without up-dosing. The new study aims to evaluate the time to oxygen normalization and hospital discharge among over 120 patients, with treatment lasting up to 14 days. Nomacopan may address severe lung inflammation, a significant issue in COVID-19 pneumonia, by targeting multiple inflammatory pathways.
Akari Therapeutics (AKTX) announced its financial results for Q2 2020, reporting a net loss of approximately $8.3 million, up from $4.1 million in the prior year. The company has cash reserves of roughly $12.7 million, boosted by recent tax credits. Akari is advancing clinical programs for nomacopan, with a Phase III trial for bullous pemphigoid set for H1 2021 and enrollment for pediatric HSCT-TMA starting in Q4 2020. Notably, clinical trials for COVID-19 pneumonia are underway in multiple countries, leveraging nomacopan's dual-action mechanism.